Reply

Affiliations

¹ Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.
² Division of Digestive and Liver Disease, UT Southwestern Medical Center, Dallas, TX.
³ Department of Public Health Sciences, University of Virginia, Charlottesville, VA.
⁴ Kidney Epidemiology and Cost Center, University of Michigan, Ann Arbor, MI.
⁵ College of Pharmacy, University of Michigan, Ann Arbor, MI.

Free article

Comment

Neehar D Parikh et al. Hepatology. 2017 Aug.

Free article

. 2017 Aug;66(2):679-680.

doi: 10.1002/hep.29248. Epub 2017 Jun 28.

¹ Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.
² Division of Digestive and Liver Disease, UT Southwestern Medical Center, Dallas, TX.
³ Department of Public Health Sciences, University of Virginia, Charlottesville, VA.
⁴ Kidney Epidemiology and Cost Center, University of Michigan, Ann Arbor, MI.
⁵ College of Pharmacy, University of Michigan, Ann Arbor, MI.

No abstract available

Comment on

Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R, Shahinian V. Parikh ND, et al. Hepatology. 2017 Jan;65(1):122-133. doi: 10.1002/hep.28881. Epub 2016 Nov 25. Hepatology. 2017. PMID: 27770556
Immortal time bias or sorafenib effect in elderly patients with HCC?
Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sanoff HK, et al. Hepatology. 2017 Aug;66(2):678-679. doi: 10.1002/hep.29250. Epub 2017 Jun 28. Hepatology. 2017. PMID: 28510340 No abstract available.